Changes to the Code
H.R. 7837 · Most Favored Patient Act of 2026 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1315a Center for Medicare and Medicaid Innovation
2 changes the bill asks for here, 2 carried out
- Carried out:
in subsection (b)(2)(A), by inserting
, and, beginning January 1, 2029, shall include the Most Favored Nations Pricing Model described in subsection (h)
before the period at the end; and - Carried out:
by adding at the end the following new subsection:
(h) Most Favored Nations Pricing Model.— (1) In general.— For purposes of subsection (b)(2)(A), the Most Favored Nations Pricing Model described in this subsection is a model under which, subject to paragraph (2), each specified manufacturer— (A) provides access to the …
§ 1315a(b)Testing of models (phase I)(1)–(2)
Start of § 1315a to (b) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1) | (1) In general | (1) In general | ||
| The CMI shall test payment and service delivery models in accordance with selection criteria under paragraph (2) to determine the effect of applying such models under the applicable subchapter (as defined in subsection (a)(4)(B)) on program expenditures under such subchapters and the quality of care received by individuals receiving benefits under such subchapter. | The CMI shall test payment and service delivery models in accordance with selection criteria under paragraph (2) to determine the effect of applying such models under the applicable subchapter (as defined in subsection (a)(4)(B)) on program expenditures under such subchapters and the quality of care received by individuals receiving benefits under such subchapter. | |||
| (2) | (2) Selection of models to be tested | (2) Selection of models to be tested | ||
| (2)(A) | (A) In general | (A) In general | ||
| The Secretary shall select models to be tested from models where the Secretary determines that there is evidence that the model addresses a defined population for which there are deficits in care leading to poor clinical outcomes or potentially avoidable expenditures. The Secretary shall focus on models expected to reduce program costs under the applicable subchapter while preserving or enhancing the quality of care received by individuals receiving benefits under such subchapter. The models selected under this subparagraph may include, but are not limited to, the models described in subparagraph (B). | The Secretary shall select models to be tested from models where the Secretary determines that there is evidence that the model addresses a defined population for which there are deficits in care leading to poor clinical outcomes or potentially avoidable expenditures. The Secretary shall focus on models expected to reduce program costs under the applicable subchapter while preserving or enhancing the quality of care received by individuals receiving benefits under such subchapter. The models selected under this subparagraph may include, but are not limited to, the models described in subparagraph (B)[inserted: , and, beginning January 1, 2029, shall include the Most Favored Nations Pricing Model described in subsection (h)]. | |||
| (2)(B) | (B) Opportunities | (B) Opportunities | ||
| The models described in this subparagraph are the following models: | The models described in this subparagraph are the following models: | |||
| (2)(B)(i) | (i) | (i) | ||
| Promoting broad payment and practice reform in primary care, including patient-centered medical home models for high-need applicable individuals, medical homes that address women’s unique health care needs, and models that transition primary care practices away from fee-for-service based reimbursement and toward comprehensive payment or salary-based payment. | Promoting broad payment and practice reform in primary care, including patient-centered medical home models for high-need applicable individuals, medical homes that address women’s unique health care needs, and models that transition primary care practices away from fee-for-service based reimbursement and toward comprehensive payment or salary-based payment. |
§ 1315a(f)–(h)
(b)(2)(B)(ii)–(f)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (f)(2) | (2) Use of certain funds | (2) Use of certain funds | ||
| Out of amounts appropriated under subparagraphs (B) and (C) of paragraph (1), not less than $25,000,000 shall be made available each such fiscal year to design, implement, and evaluate models under subsection (b). | Out of amounts appropriated under subparagraphs (B) and (C) of paragraph (1), not less than $25,000,000 shall be made available each such fiscal year to design, implement, and evaluate models under subsection (b). | |||
| (g) | (g) Report to Congress | (g) Report to Congress | ||
| Beginning in 2012, and not less than once every other year thereafter, the Secretary shall submit to Congress a report on activities under this section. Each such report shall describe the models tested under subsection (b), including the number of individuals described in subsection (a)(4)(A)(i) and of individuals described in subsection (a)(4)(A)(ii) participating in such models and payments made under applicable subchapters for services on behalf of such individuals, any models chosen for expansion under subsection (c), and the results from evaluations under subsection (b)(4). In addition, each such report shall provide such recommendations as the Secretary determines are appropriate for legislative action to facilitate the development and expansion of successful payment models. | Beginning in 2012, and not less than once every other year thereafter, the Secretary shall submit to Congress a report on activities under this section. Each such report shall describe the models tested under subsection (b), including the number of individuals described in subsection (a)(4)(A)(i) and of individuals described in subsection (a)(4)(A)(ii) participating in such models and payments made under applicable subchapters for services on behalf of such individuals, any models chosen for expansion under subsection (c), and the results from evaluations under subsection (b)(4). In addition, each such report shall provide such recommendations as the Secretary determines are appropriate for legislative action to facilitate the development and expansion of successful payment models. | |||
| (h) | (h) [inserted: Most Favored Nations Pricing Model.—] | |||
| (h)(1) | (1) [inserted: In general.—] | |||
| [inserted: For purposes of subsection (b)(2)(A), the Most Favored Nations Pricing Model described in this subsection is a model under which, subject to paragraph (2), each specified manufacturer—] | ||||
| (h)(1)(A) | (A) [inserted: ] | |||
| [inserted: provides access to the most-favored-nation price of each covered drug of such manufacturer—] | ||||
| (h)(1)(A)(i) | (i) [inserted: ] | |||
| [inserted: to most-favored-nation price eligible individuals who with respect to such drug are described in clause (i) of paragraph (5)(D) and are dispensed such drug (and to pharmacies, mail order services, and other dispensers, with respect to such individuals who are dispensed such drugs); and] | ||||
| (h)(1)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: to hospitals, physicians, and other providers of services and suppliers with respect to most-favored-nation price eligible individuals who with respect to such drug are described in clause (ii) of such paragraph furnished or administered such drug; and] | ||||
| (h)(1)(B) | (B) [inserted: ] | |||
| [inserted: reports to the Secretary, at such time and in such manner as the Secretary shall specify, such information as the Secretary determines necessary for purposes of calculating the most-favored-nation price with respect to each such covered drug.] | ||||
| (h)(2) | (2) [inserted: Exception.—] | |||
| [inserted: The Secretary may suspend the requirements under paragraph (1) with respect to a covered drug of a specified manufacturer until April 1, 2029, if the Secretary reasonably believes that such manufacturer is likely to enter into a covered agreement with the Secretary before such date.] | ||||
| (h)(3) | (3) [inserted: Duration.—] | |||
| [inserted: The model described in paragraph (1) shall be carried out for a period of 5 years.] | ||||
| (h)(4) | (4) [inserted: Definitions.—] | |||
| [inserted: In this subsection:] | ||||
| (h)(4)(A) | (A) [inserted: Applicable net price.—] | |||
| [inserted: The term “applicable net price” means, with respect to a covered drug and a reference country in which such drug was sold during a year, the average price paid to the manufacturer for the drug across package sizes and package types of the drug in such reference country during such year across all purchasers, taking into account all manufacturer rebates, discounts, and price concessions, and adjusted to take into account differences in purchasing power in such country compared to the United States in a manner specified by the Secretary.] | ||||
| (h)(4)(B) | (B) [inserted: Appropriate congressional committees.—] | |||
| [inserted: The term “appropriate congressional committees” means—] | ||||
| (h)(4)(B)(i) | (i) [inserted: ] | |||
| [inserted: the Committee on Energy and Commerce and the Committee on Ways and Means of the House of Representatives; and] | ||||
| (h)(4)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: the Committee on Finance and the Committee on Health, Education, Labor, and Pensions of the Senate.] | ||||
| (h)(4)(C) | (C) [inserted: Covered agreement.—] | |||
| [inserted: The term “covered agreement” means an agreement between a manufacturer of a covered drug and the Secretary that—] | ||||
| (h)(4)(C)(i) | (i) [inserted: ] | |||
| [inserted: provides that such manufacturer—] | ||||
| (h)(4)(C)(i)(I) | (I) [inserted: ] | |||
| [inserted: will provide access to the most-favored-nation price of 1 or more covered drugs of such manufacturer in the same manner as described in paragraph (1)(A);] | ||||
| (h)(4)(C)(i)(II) | (II) [inserted: ] | |||
| [inserted: will report to the Secretary the information described in paragraph (1)(B) with respect to each such drug; and] | ||||
| (h)(4)(C)(i)(III) | (III) [inserted: ] | |||
| [inserted: commits, to the satisfaction of the Secretary, to increasing manufacturing operations in the United States; and] | ||||
| (h)(4)(C)(ii) | (ii) [inserted: ] | |||
| [inserted: is—] | ||||
| (h)(4)(C)(ii)(I) | (I) [inserted: ] | |||
| [inserted: entered into not later than December 31, 2028; and] | ||||
| (h)(4)(C)(ii)(II) | (II) [inserted: ] | |||
| [inserted: reported by the Secretary to the appropriate congressional committees—] | ||||
| (h)(4)(C)(ii)(II)(aa) | (aa) [inserted: ] | |||
| [inserted: not later than April 1, 2029; or] | ||||
| (h)(4)(C)(ii)(II)(bb) | (bb) [inserted: ] | |||
| [inserted: in the case that such agreement was entered into before the date of the enactment of the Most Favored Patient Act of 2026, not later than the date that is 30 days after such date of enactment.] | ||||
| (h)(4)(D) | (D) [inserted: Covered drug.—] | |||
| [inserted: The term “covered drug” means, with respect to a year, a specified drug that was sold in 2 or more reference countries during such year.] | ||||
| (h)(4)(E) | (E) [inserted: Manufacturer.—] | |||
| [inserted: The term “manufacturer” has the meaning given such term in section 1847A(c)(6)(A).] | ||||
| (h)(4)(F) | (F) [inserted: Most-favored-nation price.—] | |||
| [inserted: The term “most-favored-nation price” means, with respect to a covered drug and a year, the second-lowest applicable net price for such drug.] | ||||
| (h)(4)(G) | (G) [inserted: Most-favored-nation price eligible individual.—] | |||
| [inserted: The term “most-favored-nation price eligible individual” means, with respect to a covered drug—] | ||||
| (h)(4)(G)(i) | (i) [inserted: ] | |||
| [inserted: in the case such drug is dispensed to the individual at a pharmacy, by a mail order service, or by another dispenser, an individual—] | ||||
| (h)(4)(G)(i)(I) | (I) [inserted: ] | |||
| [inserted: who is eligible for medical assistance under a State plan (or a waiver of such plan) under title XIX if coverage is provided under such plan (or waiver) for such covered drug; or] | ||||
| (h)(4)(G)(i)(II) | (II) [inserted: ] | |||
| [inserted: who is enrolled in a prescription drug plan under part D of title XVIII or an MA–PD plan under part C of such title if coverage is provided under such plan for such covered drug; and] | ||||
| (h)(4)(G)(ii) | (ii) [inserted: ] | |||
| [inserted: in the case such drug is furnished or administered to the individual by a hospital, physician, or other provider of services or supplier, an individual who is enrolled under part B of title XVIII, including an individual who is enrolled in an MA plan under part C of such title, if payment may be made under part B for such selected drug.] | ||||
| (h)(4)(H) | (H) [inserted: Reference country.—] | |||
| [inserted: The term “reference country” means any of the following countries:] | ||||
| (h)(4)(H)(i) | (i) [inserted: ] | |||
| [inserted: Canada.] | ||||
| (h)(4)(H)(ii) | (ii) [inserted: ] | |||
| [inserted: Denmark.] | ||||
| (h)(4)(H)(iii) | (iii) [inserted: ] | |||
| [inserted: France.] | ||||
| (h)(4)(H)(iv) | (iv) [inserted: ] | |||
| [inserted: Germany.] | ||||
| (h)(4)(H)(v) | (v) [inserted: ] | |||
| [inserted: Italy.] | ||||
| (h)(4)(H)(vi) | (vi) [inserted: ] | |||
| [inserted: Japan.] | ||||
| (h)(4)(H)(vii) | (vii) [inserted: ] | |||
| [inserted: Switzerland.] | ||||
| (h)(4)(H)(viii) | (viii) [inserted: ] | |||
| [inserted: The United Kingdom.] | ||||
| (h)(4)(I) | (I) [inserted: Specified drug.—] | |||
| [inserted: The term “specified drug” means—] | ||||
| (h)(4)(I)(i) | (i) [inserted: ] | |||
| [inserted: a covered outpatient drug (as defined in section 1927(k));] | ||||
| (h)(4)(I)(ii) | (ii) [inserted: ] | |||
| [inserted: a drug or biological product for which payment may be made under part B of title XVIII; or] | ||||
| (h)(4)(I)(iii) | (iii) [inserted: ] | |||
| [inserted: a covered part D drug (as defined in section 1860D–2(e)).] | ||||
| (h)(4)(J) | (J) [inserted: Specified manufacturer.—] | |||
| [inserted: The term “specified manufacturer” means a manufacturer of a covered drug that does not have a covered agreement with the Secretary.] | ||||